SELLAS Life Sciences Group (SLS) Corporate presentation summary
Event summary combining transcript, slides, and related documents.
Corporate presentation summary
17 Nov, 2026Pipeline overview
Two clinical-stage assets target AML: GPS, a WT1-directed immunotherapy, and SLS009 (tambiciclib), a selective CDK9 inhibitor.
GPS targets WT1, expressed in ~97% of AML patients, and is designed to elicit CD4+ and CD8+ responses across ~90% of human HLA types.
SLS009 showed 95% CDK9 suppression with limited off-target suppression; its development also explores hematologic and solid tumors.
GPS clinical program
In the Phase 2 CR2 AML study, median OS was 21.0 months with GPS vs 5.4 months with standard of care (p<0.02); median relapse-free survival was 10.5 vs 4.3 months.
In the Phase 3 REGAL trial, the January 2025 interim review found potential efficacy and supported continuation; 72 of 80 events had occurred as of Dec. 26, 2025, with final analysis planned at 80 events.
REGAL compares GPS with best available therapy in AML CR2/CRp2 or later remission among patients unable or ineligible for allogeneic transplant; primary endpoint is OS.
In relapsed/refractory ovarian cancer, GPS plus pembrolizumab showed 50.1% disease control, median PFS of 12 weeks and median OS of 18.4 months at 14.4-month median follow-up.
In relapsed/refractory mesothelioma, GPS plus nivolumab produced median OS of 70.3 weeks in nine combination-treated patients; median PFS was 11.9 weeks in all 10 patients.
SLS009 clinical program
Phase 2 SLS009 plus azacitidine/venetoclax met all primary endpoints; the selected regimen was 30 mg twice weekly, with no dose-limiting toxicities or treatment-related grade 3+ toxicities reported.
At 30 mg twice weekly, ORR was 41% across r/r AML cohorts, 44% in AML with myelodysplasia-related changes and 50% in AML-MR with M4/M5 features.
At 30 mg twice weekly, median OS was 8.8 months across r/r AML and 8.9 months in r/r AML-MR patients, versus a stated historical benchmark of 2.4 months for r/r AML.
ASH 2025 expansion data showed 44% ORR across AML-MR cohorts and 58% ORR among patients with one prior line of therapy.
In a Phase 1 lymphoma cohort, SLS009 showed a 14.7% clinical response rate overall, 35.3% disease control and 36.4% clinical response in PTCL; RP2D was 100 mg once weekly.
Latest events from SELLAS Life Sciences Group
- GPS met REGAL’s OS endpoint as SLS009 advances across AML settings.SLS
Corporate presentation - REGAL: GPS cut death risk 41% and extended median OS to 24.0 months.SLS
Study result - REGAL topline results are expected in November as SLS009 advances, with $134.7 million in cash.SLS
Q3 2026 - Net loss rose to $18.0M in H1 2026; cash reached $138.3M as clinical programs advanced.SLS
Q2 2026 - All proposals passed amid strong financial growth and clinical progress toward pivotal milestones.SLS
AGM 2026 - Pivotal AML trial data for GPS and phase II results for SLS009 are expected to drive major milestones.SLS
7th Annual Oncology Innovation Summit: Insights for ASCO & EHA - Pivotal data for GPS and SLS-009 in AML expected by year-end, backed by strong financials.SLS
A.G.P.'s Annual Virtual Healthcare Conference - Imminent phase III and II data for GPS and SLS009 in AML signal major near-term catalysts.SLS
Stifel 2026 Targeted Oncology Virtual Forum - GPS and SLS009 advance as late-stage, first-in-class AML therapies with pivotal data imminent.SLS
R&D Day 2025